Skip to content

Nirogacestat

Gamma Secretase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: nirogacestat hydrobromide, ogsiveo, PF-03084014, PF-03084014-04

OnpFDA approvedOrphan designationATC L01XX81

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Nirogacestat is an onp drug in the Gamma Secretase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2023. Its mechanism of action is classified as Cytochrome P450 2C19 Inducers, Cytochrome P450 3A Inhibitors and Gamma Secretase Inhibitors. DrugCentral lists 1 molecular target, including PSEN1. Recorded indications include Progressing desmoid tumors.

  • Approval status: onp (first approved 2023 by the FDA).
  • Drug class: Gamma Secretase Inhibitor.
  • Mechanism of action: Cytochrome P450 2C19 Inducers; Cytochrome P450 3A Inhibitors; Gamma Secretase Inhibitors.
  • Molecular targets: PSEN1 (1 listed in DrugCentral).
  • Indications: Progressing desmoid tumors.
  • ATC code: L01XX81 (Other antineoplastic agents).
  • Molecular formula: C27H41F2N5O; molecular weight 489.66 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Progressing desmoid tumors

Mechanism & targets

Mechanism of action (MoA)Cytochrome P450 2C19 Inducers; Cytochrome P450 3A Inhibitors; Gamma Secretase Inhibitors
Established pharmacologic classGamma Secretase Inhibitor

Molecular targets (1)

TargetGeneActionActivity
Presenilin-1PSEN1inhibitorIC50 8.21

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2023-11-27FDA—SPRINGWORKSYes

ATC classification

ATC codeTherapeutic hierarchy
L01XX81ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label: APC, CTNNB1
  • FDA label: APC, CTNNB1
  • HCSC label: APC, CTNNB1

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Diarrhoea121.1
Hidradenitis92.7
Hypophosphataemia55.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nirogacestat is on its molecule page.

Molecular formulaC27H41F2N5O
Molecular weight489.66 g/mol
CAS number1290543-63-3
InChIKeyVFCRKLWBYMDAED-REWPJTCUSA-N
PubChem CID46224413
CCC[C@H](N[C@H]1CCC2=CC(F)=CC(F)=C2C1)C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nirogacestat used for?

DrugCentral lists the following indications for Nirogacestat: Progressing desmoid tumors.

How does Nirogacestat work?

Nirogacestat is classified as Cytochrome P450 2C19 Inducers, Cytochrome P450 3A Inhibitors and Gamma Secretase Inhibitors; its molecular targets in DrugCentral include PSEN1 (inhibitor).

When was Nirogacestat first approved?

Nirogacestat was first approved by the FDA in 2023.

What drug class does Nirogacestat belong to?

Nirogacestat is in the Gamma Secretase Inhibitor class.

What is the chemical formula of Nirogacestat?

Nirogacestat has the molecular formula C27H41F2N5O and a molecular weight of 489.66 g/mol.

Browse: all drugs starting with N · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2023-11-27
AgencyFDA
Targets1
Indications1
FormulaC27H41F2N5O
DrugCentral ID5753
Interactive profile